- Home
- ALEC vs WIA Comparison
ALEC vs WIA Comparison
Compare ALEC & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALEC | WIA |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 184.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALEC | WIA |
|---|---|---|
| Price | $2.03 | $8.03 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.83 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 31.0K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.29% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,045,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $29.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $7.90 |
| 52 Week High | $3.40 | $8.54 |
Technical Indicators
Market Signals| Indicator | ALEC | WIA |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 51.84 |
| Support Level | $1.93 | $7.95 |
| Resistance Level | $2.10 | $8.31 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 81.94 | 79.24 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.